Your browser doesn't support javascript.
loading
Biological treatment in Felty's syndrome with profound neutropenia.
Proc, Krzysztof; Madej, Marta; Wiland, Piotr; Sebastian, Agata.
Affiliation
  • Proc K; Department of Rheumatology and Internal Medicine, Medical University Hospital, Wroclaw, Poland.
  • Madej M; Department of Rheumatology and Internal Medicine, Wroclaw Medical University, Poland.
  • Wiland P; Department of Rheumatology and Internal Medicine, Wroclaw Medical University, Poland.
  • Sebastian A; Department of Rheumatology and Internal Medicine, Wroclaw Medical University, Poland.
Reumatologia ; 61(3): 213-218, 2023.
Article in En | MEDLINE | ID: mdl-37522143
ABSTRACT
A triad of symptoms characterises Felty's syndrome seropositive rheumatoid arthritis (RA), splenomegaly and neutropenia. The treatment of Felty's syndrome is based on using classic synthetic and biological disease-modifying anti-rheumatic drugs (DMARDs). In this article, we present a case of a patient with Felty's syndrome who was treated with biologic treatment. A systematic search of the literature on the electronic medical database was conducted. The drugs from the DMARD group, despite reducing the activity of the disease, may cause significant clinical complications. It is important to know about the diagnosis, differentiation and treatment of neutropenia and the prevention of febrile neutropenia. The article discusses the current therapeutic possibilities using both classical and biologic DMARDs.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Reumatologia Year: 2023 Document type: Article Affiliation country: Polonia

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Reumatologia Year: 2023 Document type: Article Affiliation country: Polonia